Parkinson Disease

In this segment, Pagan shared strategies to enhance patient adherence and comfort with long-term CSAI use, and offered his perspective on the evolving role of CSAI in managing complex motor fluctuations in Parkinson disease.

Panelists discuss how pharmacokinetic challenges with oral levodopa formulations have led to the development of levodopa-based continuous subcutaneous infusion therapy as a less invasive and more personalized approach.

Explore the latest advancements in cell and gene therapies for Parkinson disease, featuring cutting-edge treatments and clinical trial updates from top innovators in the field.

The REGENERATE-PD trial is a phase 2 study assessing the safety and efficacy of the investigational gene therapy AB-1005 in patients with moderate-stage Parkinson disease.

Panelists discuss how physicians approach conversations about off time with patients with Parkinson disease, balancing clinical assessment with patient education and shared decision-making.

Panelists discuss how understanding and communication of off episodes for patients with Parkinson disease varies widely in clinical settings, often hindering optimal symptom management.

The chief scientific officer of the Parkinson’s Foundation talked about how broad genetic testing through PD GENEration is uncovering valuable prognostic and diagnostic insights in Parkinson disease. [WATCH TIME: 4 minutes]

Pooled analysis from KINECT-3 and KINECT-4 confirms valbenazine’s long-term safety and efficacy in managing tardive dyskinesia in elderly patients.

Pagan offered advice to early-career neurologists on how to stay current in the rapidly evolving field, emphasizing the importance of attending meetings and continuing education.

Pagan talked about discussed pharmacokinetic-pharmacodynamic data supporting the use of amantadine ER for dyskinesia in Parkinson disease and compared the safety profiles of rasagiline and safinamide to guide add-on therapy decisions.

NLX-112 demonstrated safety and potential efficacy in reducing levodopa-induced dyskinesia and improving motor symptoms in Parkinson disease, with additional benefits seen in patients also receiving stable amantadine.

Panelists discuss how limitations persist with current long-term treatment standards for Parkinson disease despite advancements in treatment options.

Panelists discuss how alternative formulations and administration routes like Levodopa/carbidopa intestinal gel and deep brain stimulation have impacted advanced Parkinson disease management, including which patient populations benefit most and when these options are recommended.

In this segment, Pagan talked about how the field of neurology has changed in the last decade and shared where he sees it moving forward as well.

Pagan shared insights from InfusON patient interviews on the challenges and benefits of initiating CSAI therapy and discussed how expert roundtable recommendations can guide neurologists in managing skin nodules associated with treatment.

Panelists discuss how treatment changes in Parkinson disease are necessitated by disease progression, diminishing medication effectiveness, and emerging motor complications, examining a physician’s systematic approach to treatment adjustments and the range of available options for managing off fluctuations.

Panelists discuss how off fluctuations in Parkinson disease become increasingly prevalent as the disease progresses, significantly impacting patient quality of life through reduced mobility, independence, and overall well-being.

In this phase 2 trial, TTNS using the Geko device was safe and well tolerated but showed no significant benefit over sham in improving urinary symptoms in Parkinson disease.

Pagan discusses the excitement surrounding new therapeutics in neurodegenerative diseases and how advances in protein clearance and inflammation reduction could lead to disease-modifying treatments for conditions like Parkinson disease.

Panelists discuss how medical professionals adjust treatment regimens and create individualized plans as Parkinson disease advances in their patients.

Panelists discuss how medical professionals determine the most appropriate treatment options for patients with advanced Parkinson disease and the challenges patients face as their disease progresses over time.

Fernando L. Pagan, MD, discussed how continuous subcutaneous apomorphine infusion impacts long-term motor fluctuations in Parkinson disease, highlighting InfusON extension study findings on uninterrupted "good ON" time and reduced "OFF" periods as evidence of its real-world efficacy.

The chief scientific officer of the Parkinson’s Foundation discussed the foundation’s efforts to integrate whole genome sequencing into PD GENEration and expand access across diverse global populations. [WATCH TIME: 4 minutes]

Findings from a phase 3 study revealed that patients with Parkinson disease switching to IPX203 had greater benefits in good ON time when also taking lower doses of dopamine agonists.

Presented at the 2025 AD/PD Conference, the study incorporates patient engagement in its design and implementation, focusing on optimizing study accessibility, reducing burden, and evaluating glovadalen’s potential as an adjunctive treatment for PD.